Clinical trial
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
NCT02000440 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 1, 2014
- Completion date
- May 11, 2016
- Enrollment
- 17 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.